Evidence map›Paper›PMID 34452474›Full record

ArticleViruses2021

A Gut Reaction to SIV and SHIV Infection: Lower Dysregulation of Mucosal T Cells during Acute Infection Is Associated with Greater Viral Suppression during cART.

Megan A O'Connor, Paul V Munson, Sandra E Dross, Hillary C Tunggal, Thomas B Lewis, Jessica Osborn, Christopher W Peterson, Meei-Li W Huang, Cassandra Moats, Jeremy Smedley and 5 more

Abstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Megan A O'ConnorDepartment of Microbiology, University of Washington, 750 Republican St., Seattle, WA 98109, USA.ORCID 0000-0003-2127-5073
Paul V MunsonDepartment of Microbiology, University of Washington, 750 Republican St., Seattle, WA 98109, USA.
Sandra E DrossDepartment of Microbiology, University of Washington, 750 Republican St., Seattle, WA 98109, USA.
Hillary C TunggalDepartment of Microbiology, University of Washington, 750 Republican St., Seattle, WA 98109, USA.
Thomas B LewisDepartment of Microbiology, University of Washington, 750 Republican St., Seattle, WA 98109, USA.
Jessica OsbornDepartment of Microbiology, University of Washington, 750 Republican St., Seattle, WA 98109, USA.
Christopher W PetersonStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA.
Meei-Li W HuangDepartment of Laboratory Medicine and Pathology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA.ORCID 0000-0002-2861-8035
Cassandra MoatsWashington National Primate Research Center, 1705 NE Pacific Street, Seattle, WA 98195, USA.
Jeremy SmedleyWashington National Primate Research Center, 1705 NE Pacific Street, Seattle, WA 98195, USA.ORCID 0000-0003-3369-4662
Keith R JeromeStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA.
Hans-Peter KiemStem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA.
Kenneth C BagleyProfectus Biosciences Inc., 6411 Beckley Street, Baltimore, MD 21224, USA.
James I MullinsDepartment of Microbiology, University of Washington, 750 Republican St., Seattle, WA 98109, USA.
Deborah Heydenburg FullerDepartment of Microbiology, University of Washington, 750 Republican St., Seattle, WA 98109, USA.ORCID 0000-0001-7315-2441

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Cell and Gene Therapy for HIV CureUM1AI126623 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JEROME, KEITH R, KIEM, HANS-PETER · 2016 to 2020
$24.2M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Conserved Elements Therapeutic DNA Vaccine for HIVR01AI104679 · NIAID · UNIVERSITY OF WASHINGTON · PI FULLER, DEBORAH H., MULLINS, JAMES IVAN · 2013 to 2016
$3.9M
Optimization of a Therapeutic HIVSIV Multi-Antigen DNA VaccineR44AI110315 · NIAID · PROFECTUS BIOSCIENCES, INC. · PI BAGLEY, KENNETH C · 2014 to 2017
$3.1M
NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI104679NIAID NIH HHS R44 AI110315NIAID NIH HHS T32 AI007140NIAID NIH HHS UM1 AI126623NIH HHS P51 OD010425NIH HHS R44 AI110315NIH HHS RO1 AI104679NIH HHS T32-AI007140NIH HHS UM1 AI126623
6 · The paper itself

Abstract

Selection of a pre-clinical non-human primate (NHP) model is essential when evaluating therapeutic vaccine and treatment strategies for HIV. SIV and SHIV-infected NHPs exhibit a range of viral burdens, pathologies, and responses to combinatorial antiretroviral therapy (cART) regimens and the choice of the NHP model for AIDS could influence outcomes in studies investigating interventions. Previously, in rhesus macaques (RMs) we showed that maintenance of mucosal Th17/Treg homeostasis during SIV infection correlated with a better virological response to cART. Here, in RMs we compared viral kinetics and dysregulation of gut homeostasis, defined by T cell subset disruption, during highly pathogenic SIVΔB670 compared to SHIV-1157ipd3N4 infection. SHIV infection resulted in lower acute viremia and less disruption to gut CD4 T-cell homeostasis. Additionally, 24/24 SHIV-infected versus 10/19 SIV-infected animals had sustained viral suppression <100 copies/mL of plasma after 5 months of cART. Significantly, the more profound viral suppression during cART in a subset of SIV and all SHIV-infected RMs corresponded with less gut immune dysregulation during acute SIV/SHIV infection, defined by maintenance of the Th17/Treg ratio. These results highlight significant differences in viral control during cART and gut dysregulation in NHP AIDS models and suggest that selection of a model may impact the evaluation of candidate therapeutic interventions for HIV treatment and cure strategies.

Indexed as

HomeostasisSustained Virologic ResponseAcute DiseaseAnimalsAnti-Retroviral AgentsGastrointestinal TractImmunity, MucosalIntraepithelial LymphocytesKineticsMacaca mulattaMaleModels, AnimalSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusTh17 CellsT-Lymphocytes, RegulatoryAnti-Retroviral AgentsAIDS modelscARTcolonmucosal dysfunctionnon-human primate (NHP)SHIVSIVT helper 17 (Th17)T regulatory

Identifiers

PMID34452474
PMCPMC8402906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.